SS-31 (Elamipretide): Targeting Mitochondrial Dysfunction
Mitochondrial Peptides
FDA approved
Elamipretide received accelerated FDA approval in September 2025 for Barth syndrome, becoming the first mitochondria-targeted peptide therapeutic approved in the United States.
FDA accelerated approval, September 19, 2025
FDA accelerated approval, September 19, 2025
View as imageMitochondria produce over 90% of the energy your cells need to function. When they fail, the consequences ripple across every organ system: the heart weakens, muscles fatigue, nerves degenerate, and kidneys lose function. SS-31, now known by its drug name elamipretide, is a synthetic tetrapeptide that concentrates inside mitochondria and binds cardiolipin, a lipid essential for maintaining the structure of the inner mitochondrial membrane. In September 2025, elamipretide became the first mitochondria-targeted peptide to receive FDA approval, granted under the accelerated pathway for Barth syndrome, a rare genetic disorder of cardiolipin metabolism. For the broader context of mitochondrial peptides, see the pillar article on humanin, the cytoprotective peptide from mitochondria.
Key Takeaways
- SS-31 (D-Arg-Dmt-Lys-Phe-NH2) selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and improving electron transport chain efficiency[1]
- FDA-approved for Barth syndrome in September 2025 after clinical trials showed improved 6-Minute Walk Test performance, cardiac stroke volume, and cardiolipin levels over 48 weeks
- In aged mice, 8 weeks of elamipretide almost completely reversed age-related oxidative modifications of heart proteins[2]
- SS-31 improved mitochondrial ADP sensitivity in aged skeletal muscle, a key functional deficit in age-related muscle decline[3]
- Preclinical evidence spans diabetic nephropathy, traumatic brain injury, cardiac hypertrophy, atherosclerosis, and age-related glomerular decline
- Phase 3 trials for primary mitochondrial myopathy and age-related macular degeneration are ongoing
What SS-31 Is and How It Reaches Mitochondria
SS-31 is a tetrapeptide: D-arginine, 2',6'-dimethyltyrosine (Dmt), lysine, phenylalanine, with a C-terminal amide. The D-arginine and Dmt residues are non-natural, which protects the peptide from rapid enzymatic degradation.
The peptide's ability to concentrate inside mitochondria comes from its alternating aromatic-cationic motif. The two positive charges (from arginine and lysine) are attracted by the large negative membrane potential across the inner mitochondrial membrane (approximately -180 mV). This electrochemical gradient drives SS-31 accumulation inside mitochondria at concentrations 1,000-fold or more above extracellular levels.
Mitchell et al. (2020) characterized the biophysical mechanism: SS-31 partitions into the lipid bilayer interface and modulates surface electrostatics in a charge-dependent manner rather than simply passing through the membrane.[1] Once at the inner membrane, it binds cardiolipin, a phospholipid found almost exclusively in mitochondria that is essential for cristae formation and electron transport chain assembly.
The Cardiolipin Connection
Cardiolipin is not just another membrane lipid. It anchors the electron transport chain complexes in the correct orientation and maintains the folds (cristae) of the inner membrane that maximize ATP production surface area. When cardiolipin is damaged by oxidation or depleted by genetic mutation, the electron transport chain becomes inefficient, producing less ATP and more reactive oxygen species (ROS).
In Barth syndrome, mutations in the TAFAZZIN gene prevent proper cardiolipin remodeling. The resulting cardiolipin deficiency causes cardiomyopathy, skeletal muscle weakness, neutropenia, and growth failure, typically presenting in childhood. SS-31 binds the remaining cardiolipin and stabilizes its interactions with the electron transport chain, partially compensating for the underlying genetic defect.
Russo et al. (2022) demonstrated this in tafazzin-knockdown mice: SS-31 improved mitochondrial respiratory capacity without affecting the ratio of monolysocardiolipin to cardiolipin (the biochemical hallmark of Barth syndrome).[4] This means SS-31 works downstream of the genetic defect, improving function from the cardiolipin that is present rather than correcting the underlying biosynthetic problem.
FDA Approval for Barth Syndrome
On September 19, 2025, the FDA granted accelerated approval to elamipretide for Barth syndrome. The approval was based on clinical trial data showing:
- Improved performance on the 6-Minute Walk Test over 48 weeks
- Increased cardiac stroke volume
- Improved cardiolipin levels compared to baseline
- Reduced fatigue reported by participants on the BTHS Symptom Assessment Scale
The accelerated approval pathway requires confirmatory trials. Elamipretide must still demonstrate clinical benefit in additional studies to maintain its approval. The Barth Syndrome Foundation played a central role in advocating for clinical development and trial design.
This approval is significant beyond Barth syndrome. It validates the principle that a small peptide targeting mitochondrial membrane lipids can produce measurable clinical benefit in a disease of mitochondrial dysfunction. Whether this translates to other conditions where mitochondrial dysfunction contributes to pathology (aging, heart failure, neurodegeneration) is the central question driving ongoing trials.
Aging Evidence
Heart
Whitson et al. (2021) treated aged mice with elamipretide for 8 weeks and measured post-translational modifications of heart proteins. The treatment almost completely reversed age-related increases in S-glutathionylation, a type of oxidative modification that impairs protein function in aging hearts.[2] This reversal of oxidative protein damage in an aged organ is among the most striking findings in the SS-31 literature.
Skeletal muscle
Pharaoh et al. (2023) showed that elamipretide improved ADP sensitivity in aged mitochondria from skeletal muscle.[3] ADP sensitivity is a measure of how efficiently mitochondria respond to energy demand. In aged muscle, mitochondria become sluggish in their response to ADP, which contributes to fatigue and exercise intolerance. Restoring ADP sensitivity could address one of the fundamental mechanisms of age-related muscle decline.
Kidney
Sweetwyne et al. (2017) demonstrated that SS-31 improved glomerular architecture in mice of advanced age, reversing structural changes in the kidney's filtration units that accumulate during aging.[5] Hou et al. (2016) showed the peptide attenuated renal injury in diabetic mice by reducing proteinuria, oxidative DNA damage, renal fibrosis, and apoptosis via inhibition of NADPH oxidase pathways.[6]
The convergence of heart, muscle, and kidney data in aging models is consistent with mitochondrial dysfunction as a shared mechanism across organ systems. SS-31 appears to address this common denominator rather than targeting any single disease pathway.
Neuroprotection
Zhu et al. (2018) tested SS-31 in a traumatic brain injury model and found it reversed mitochondrial dysfunction, reduced oxidative stress, and provided neuroprotection when administered 30 minutes post-injury.[7]
Zuo et al. (2020) showed elamipretide attenuated pyroptosis (inflammatory cell death) and prevented perioperative neurocognitive disorders in aged mice. The peptide protected against surgery-induced mitochondrial dysfunction, NLRP3 inflammasome activation, synaptic protein downregulation, and cognitive deficits in the hippocampus.[8]
These neuroprotection findings connect SS-31 to the broader landscape of mitochondrial-derived peptides as anti-aging molecules, though SS-31 is a synthetic peptide rather than one encoded in the mitochondrial genome.
Cardiovascular Protection
Beyond the age-reversal data, SS-31 has been tested in models of active cardiovascular disease.
Lu et al. (2016) demonstrated that SS-31 attenuated pulmonary arterial hypertension induced by transverse aortic constriction, a model of pressure-overload heart failure.[9]
Zhang et al. (2017) showed chronic SS-31 administration prevented atherosclerotic development in apoE-knockout mice, linking mitochondrial protection to reduced vascular plaque formation.[10]
Thomas et al. (2007) provided early evidence that SS-31 prevents mitochondrial depolarization and reduces apoptosis in pancreatic islet cells, preserving insulin secretion in diabetic models.[11]
Metabolic and Anti-Inflammatory Effects
Beyond organ-specific protection, SS-31 shows effects on systemic metabolic and inflammatory pathways.
Thomas et al. (2007) demonstrated that SS-31 prevented mitochondrial depolarization in pancreatic islet cells and preserved glucose-stimulated insulin secretion in diabetic models, suggesting a role in maintaining beta cell function under metabolic stress.[11]
Hao et al. (2015) showed SS-31 inhibited oxidized LDL-induced foam cell formation, a critical early step in atherosclerotic plaque development. The peptide's antioxidant effect within macrophage mitochondria prevented the lipid accumulation that transforms macrophages into the foam cells that build arterial plaques.[12]
Li et al. (2016) tested SS-31 during endotoxemia (sepsis model) and found it protected against multiple organ dysfunction by maintaining mitochondrial function under severe inflammatory stress.[13] This suggests SS-31's protective mechanism is not limited to chronic conditions; it can also mitigate acute mitochondrial crisis.
Du et al. (2024) reviewed the application of SS-31 across multiple disease models and highlighted its consistent ability to reduce mitochondrial ROS production, preserve membrane potential, and improve respiratory chain efficiency across diverse cell types and disease states.[14]
The pattern across studies is consistent: wherever mitochondrial dysfunction drives pathology, SS-31 appears to provide benefit. This breadth of preclinical efficacy is both the peptide's greatest strength (it addresses a fundamental mechanism) and its greatest liability (therapies that appear to work everywhere in mice often work nowhere in humans).
Clinical Pipeline Beyond Barth Syndrome
Elamipretide is in phase 3 clinical trials for two additional indications:
Primary mitochondrial myopathy (PMM): A group of rare genetic disorders affecting mitochondrial function in muscle. The MMPOWER trials are evaluating elamipretide's effect on exercise capacity and patient-reported outcomes.
Age-related macular degeneration (AMD): The ReCLAIM trial is testing elamipretide for dry AMD, where mitochondrial dysfunction in retinal pigment epithelium cells contributes to progressive vision loss.
Phase 2 data for heart failure with reduced ejection fraction (HFrEF) showed mixed results: elamipretide improved some measures of cardiac function but did not meet primary endpoints in larger trials. The heart failure program has been deprioritized relative to the rare disease indications.
Limitations and Open Questions
Delivery requires injection. Elamipretide is administered as a daily subcutaneous injection. Oral bioavailability is essentially zero for a charged tetrapeptide. This limits its practical use for chronic conditions like aging, where lifelong daily injections are a significant treatment burden.
The Barth approval is accelerated. Confirmatory trials must still demonstrate clinical benefit. If confirmatory data are negative, the approval could be withdrawn.
Translating preclinical aging data to humans is unproven. Mouse studies showing reversal of age-related changes in heart, muscle, and kidney are compelling but have not been replicated in human aging trials. The jump from inbred mice to genetically diverse human populations is where many promising interventions fail.
Long-term safety data are limited. The Barth syndrome trials provided 48-week data. Whether years of daily SS-31 exposure produces unexpected effects (particularly in organs with high mitochondrial turnover) is unknown.
Cost. Rare disease drugs in the United States typically cost hundreds of thousands of dollars annually. Accessibility for potential off-label anti-aging use is a practical barrier separate from the scientific questions.
Mechanism specificity. SS-31 binds cardiolipin broadly rather than targeting a specific disease-related protein. This means it could potentially affect mitochondrial function in ways that are beneficial in some contexts and neutral or harmful in others. Mitochondria in different tissues have different cardiolipin compositions, and the effects of SS-31 may vary accordingly. The Barth syndrome trials provide safety data for one specific population; other populations with different mitochondrial profiles may respond differently.
Comparison to lifestyle interventions. Exercise is the most proven intervention for maintaining mitochondrial function with age. It increases mitochondrial biogenesis, improves respiratory chain efficiency, and reduces oxidative stress through the same general pathways that SS-31 targets pharmacologically. Whether SS-31 adds benefit beyond exercise, or whether it could serve as a substitute for the mitochondrial benefits of physical activity, has not been tested. The combination of SS-31 with exercise in aging populations would be a particularly informative trial design.
The Bottom Line
SS-31 (elamipretide) is a synthetic tetrapeptide that concentrates in mitochondria and binds cardiolipin to stabilize the inner mitochondrial membrane. Its FDA approval for Barth syndrome in September 2025 validates the mitochondria-targeted peptide approach. Preclinical data across heart, muscle, kidney, and brain models show consistent reversal or attenuation of mitochondrial dysfunction. The peptide improves ADP sensitivity in aged muscle, reverses oxidative protein modifications in aged hearts, and provides neuroprotection after brain injury. Phase 3 trials for mitochondrial myopathy and macular degeneration are ongoing. Whether the preclinical aging benefits translate to human anti-aging applications remains untested.